Point72 Asset Management Reports New 1.6% Stake in Alto Neuroscience, Inc. (ANRO)

On May 15, 2026, Point72 Asset Management, L.P. filed a Schedule 13G/A regarding its holdings in Alto Neuroscience, Inc. (ANRO). The filing indicates that as of March 31, 2026, Point72 Asset Management beneficially owns 503,087 shares of Common Stock, representing approximately 1.6% of the class. This reflects an increase from a previous reported position of zero shares. The filing is a joint statement involving several related entities, including Point72 Capital Advisors, Inc., Point72 Biotech Private Investments, LLC, Differentiated Ventures Investments, LLC, 72 Investment Holdings, LLC, and Steven A. Cohen. When aggregating holdings across all reporting persons, Steven A. Cohen is deemed to beneficially own a total of 1,170,865 shares, or 3.7% of the company. The shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Point72 Asset Management maintains investment and voting power over the securities through an investment management agreement.